Hepcinat-LP Tablets is a formulation combination of anti-viral medications Ledipasvir and Sofosbuvir used in the treatment of Chronic Hepatitis C Virus (CHCV) infection genotype 1. Hepcinat-LP is a prescription medicine containing Ledipasvir (90mg) a viral NS5A inhibitor and Sofosbuvir (400mg) a nucleotide inhibitor of the viral RNA polymerase.
Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase-the key enzyme mediating HCV RNA replication. The triphosphate form of Sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.
Ledipasvir - Sofosbuvir has significant medicine interactions with P-gp inducers . The concomitant use of Ledipasvir-Sofosbuvir with P-gp inducers is not recommended. Additional medicine interactions may occur with Ledipasvir-Sofosbuvir and other medications.
For Free Consulting
Phone No.- +91-120–2400370.
Mob. : + 91-8130290915
WhatsApp: +91 8130290915
Skype ID: praveen.sikri
Email ID: [email protected]